🚀 VC round data is live in beta, check it out!
Grifols Valuation Multiples
Discover revenue and EBITDA valuation multiples for Grifols and similar public comparables like Ono Pharmaceutical, Kymera Therapeutics, Alkem Laboratories, Apogee Therapeutics and more.
Grifols Overview
About Grifols
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Founded
1987
HQ
Employees
23.8K
Website
Sectors
Financials (LTM)
EV
$17B
Grifols Financials
Grifols reported last 12-month revenue of $9B and EBITDA of $2B.
In the same LTM period, Grifols generated $3B in gross profit, $2B in EBITDA, and $523M in net income.
Revenue (LTM)
Grifols P&L
In the most recent fiscal year, Grifols reported revenue of $8B and EBITDA of $2B.
Grifols expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $9B | XXX | $8B | XXX | XXX | XXX |
| Gross Profit | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Margin | 38% | XXX | 39% | XXX | XXX | XXX |
| EBITDA | $2B | XXX | $2B | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 21% | XXX | XXX | XXX |
| EBIT Margin | 18% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $523M | XXX | $185M | XXX | XXX | XXX |
| Net Margin | 6% | XXX | 2% | XXX | XXX | XXX |
| Net Debt | — | — | $9B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Grifols Stock Performance
Grifols has current market cap of $7B, and enterprise value of $17B.
Market Cap Evolution
Grifols' stock price is $10.37.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $17B | $7B | 1.5% | XXX | XXX | XXX | $0.27 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGrifols Valuation Multiples
Grifols trades at 1.9x EV/Revenue multiple, and 7.7x EV/EBITDA.
EV / Revenue (LTM)
Grifols Financial Valuation Multiples
As of April 18, 2026, Grifols has market cap of $7B and EV of $17B.
Equity research analysts estimate Grifols' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Grifols has a P/E ratio of 13.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7B | XXX | $7B | XXX | XXX | XXX |
| EV (current) | $17B | XXX | $17B | XXX | XXX | XXX |
| EV/Revenue | 1.9x | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | 7.7x | XXX | 9.6x | XXX | XXX | XXX |
| EV/EBIT | 10.6x | XXX | 12.3x | XXX | XXX | XXX |
| EV/Gross Profit | 4.9x | XXX | 5.1x | XXX | XXX | XXX |
| P/E | 13.5x | XXX | 38.2x | XXX | XXX | XXX |
| EV/FCF | 27.2x | XXX | 26.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Grifols Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Grifols Margins & Growth Rates
Grifols' revenue in the last 12 month grew by 4%.
Grifols' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Grifols' rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Grifols' rule of X is 32% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Grifols Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 23% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 28% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 32% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 16% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 6% | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 23% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Grifols Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Grifols | XXX | XXX | XXX | XXX | XXX | XXX |
| Ono Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Kymera Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Alkem Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| Apogee Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Glenmark Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Grifols M&A Activity
Grifols acquired XXX companies to date.
Last acquisition by Grifols was on XXXXXXXX, XXXXX. Grifols acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Grifols
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGrifols Investment Activity
Grifols invested in XXX companies to date.
Grifols made its latest investment on XXXXXXXX, XXXXX. Grifols invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Grifols
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Grifols
| When was Grifols founded? | Grifols was founded in 1987. |
| Where is Grifols headquartered? | Grifols is headquartered in Spain. |
| How many employees does Grifols have? | As of today, Grifols has over 23K employees. |
| Who is the CEO of Grifols? | Grifols' CEO is Jose Ignacio Abia Buenache. |
| Is Grifols publicly listed? | Yes, Grifols is a public company listed on Bolsa de Madrid. |
| What is the stock symbol of Grifols? | Grifols trades under GRF ticker. |
| When did Grifols go public? | Grifols went public in 2006. |
| Who are competitors of Grifols? | Grifols main competitors are Ono Pharmaceutical, Kymera Therapeutics, Alkem Laboratories, Apogee Therapeutics. |
| What is the current market cap of Grifols? | Grifols' current market cap is $7B. |
| What is the current revenue of Grifols? | Grifols' last 12 months revenue is $9B. |
| What is the current revenue growth of Grifols? | Grifols revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Grifols? | Current revenue multiple of Grifols is 1.9x. |
| Is Grifols profitable? | Yes, Grifols is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Grifols? | Grifols' last 12 months EBITDA is $2B. |
| What is Grifols' EBITDA margin? | Grifols' last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Grifols? | Current EBITDA multiple of Grifols is 7.7x. |
| What is the current FCF of Grifols? | Grifols' last 12 months FCF is $618M. |
| What is Grifols' FCF margin? | Grifols' last 12 months FCF margin is 7%. |
| What is the current EV/FCF multiple of Grifols? | Current FCF multiple of Grifols is 27.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.